Plante Moran Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Plante Moran Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-39	Closed	-$2.66K	–	804
2024 Q1	$2.66K	Buy	+39	New	+$2.79K	﹤0.01%	748
2020 Q3	–	Sell	-1,100	Closed	-$81K	–	851
2020 Q2	$81K	Buy	+1,100	New	+$64.3K	0.03%	236
2020 Q1	–	Sell	-5,050	Closed	-$308K	–	745
2019 Q4	$308K	Buy	+5,050	New	+$276K	0.11%	117

Other funds holding CRSP

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Plante Moran Financial Advisors's CRSP Position: Q2 2024 in Review

Plante Moran Financial Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 39 shares — an estimated $2.66K sold.

Plante Moran Financial Advisors first reported a position in CRSP in Q4 2019 and held it in 3 quarters. The position peaked at $308K in Q4 2019. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

Plante Moran Financial Advisors reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
Plante Moran Financial Advisors sold 39 CRISPR Therapeutics shares in Q2 2024, an estimated $2.66K.
Plante Moran Financial Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 3 quarters.
Plante Moran Financial Advisors's CRISPR Therapeutics position peaked at $308K in Q4 2019.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.